Zydus Receives Tentative Approval from USFDA for Colchicine Tablets

Shalini | Myequity news | Date : 18-10-2018 17:20:00 IST

Zydus Cadilahas received thetentative approval from the USFDA to market Colchicine Tablets USP(USRLD-Colcyrs), 0.6mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

This medication is used to prevent or treat attacks of gout(also called goutyarthritis).This condition is caused by high uric acid levels in the blood. An attack of gout occurs when uric acid causes inflammation(pain, redness, swelling, andheat)in a joint. This medication is also used to prevent attacks of pain in the abdomen, chestor joints caused by a genetic auto-inflammatory disease(called as familial Mediterranean fever).

The group now has 223 approvals and has so far filed over 330 AND As since the commencement of the filing process in FY2003-04.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020


More from Myequity